Table II.
Chemotherapy background of the 14 patients who received adjuvant GEM treatments.
| Age | Sex | Stage | GLI2 | Surgery | Recurrence | RT (months) | SP (months) |
|---|---|---|---|---|---|---|---|
| 59 | M | 0 | Low | C | R-LN | 30 | 44 |
| 61 | M | II | High | C | Liver | 51 | 60 |
| 63 | M | II | High | C | None | – | 60 |
| 53 | F | II | Low | C | Peritoneum | 7 | 20 |
| 53 | F | II | High | C | None | – | 60 |
| 65 | M | II | Low | C | None | – | 60 |
| 67 | F | IIIB | High | C | None | – | 60 |
| 65 | M | II | High | C | None | – | 60 |
| 73 | F | II | Low | C | Liver | 24 | 50 |
| 58 | M | IIIB | Low | N | – | – | 31 |
| 71 | F | IIIB | Low | C | PA-LN | 12 | 35 |
| 65 | M | IIIB | Low | N | – | – | 60 |
| 65 | F | IIIB | Low | N | – | – | 49 |
| 60 | M | II | Low | C | PA-LN | 48 | 60 |
GEM, gemcitabine; GLI2, glioma-associated oncogene homolog 2; GLI2, GLI2 expression; C, curative; N, non-curative; R-LN, regional lymph node; PA-LN, para-aortic lymph node; RT, duration to recurrence; SP, survival period.